ImmunityBio begins European patient treatment with Anktiva plus BCG for bladder cancer
ImmunityBio has begun treating patients in Europe with Anktiva plus BCG for a defined form of BCG-unresponsive bladder cancer, marking an early commercial-access milestone following its existing European authorisation.
The company announced on 4 November 2026 that initial patients in Germany and Austria had received Anktiva (nogapendekin alfa inbakicept) in combination with BCG for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumours.
The rollout is supported by Accord Healthcare's commercial and market-access activities and Uniphar's distribution services and follows European Commission conditional marketing authorisation granted in February 2026, making this a treatment-access milestone rather than a new approval or indication expansion.
Field | Content |
Article Type | Industry Updates |
Company | ImmunityBio |
Product | Anktiva |
Active Ingredient | Nogapendekin alfa inbakicept |
Combination Treatment | Bacillus Calmette-Guérin |
Combination Abbreviation | BCG |
Announcement Date | 4 November 2026 |
Update Type | European treatment-access and commercialisation milestone |
Commercialisation Status | First European patients treated |
Initial Treatment Countries | Germany; Austria |
Therapeutic Area | Oncology; urologic oncology |
Cancer Type | Non-muscle-invasive bladder cancer |
Abbreviation | NMIBC |
Treatment Population | BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumours |
Carcinoma in Situ Abbreviation | CIS |
Prior Treatment Context | BCG-unresponsive disease |
European Regulatory Authority | European Commission |
European Authorisation Type | Conditional marketing authorisation |
Original European Authorisation Date | February 2026 |
Regulatory Status | Previously authorised in the European Union for the specified indication |
New Regulatory Approval | No new European Commission approval announced |
Commercial Partner | Accord Healthcare |
Commercial Partner Responsibilities | Commercial and market-access activities |
Distribution Partner | Uniphar |
Distribution Partner Responsibilities | Distribution services |
What Happened | ImmunityBio confirmed that the first patients in Germany and Austria had received Anktiva plus BCG following existing European authorisation. |
Why It Matters | The announcement demonstrates early patient access to the authorised treatment in European clinical practice. |
Commercial Significance | Marks an initial European rollout milestone supported by established commercial and distribution partners. |
Regulatory Clarification | The February 2026 conditional marketing authorisation predates this announcement; no new approval or indication expansion occurred. |
Key Takeaway | Anktiva plus BCG has begun reaching European patients with BCG-unresponsive non-muscle-invasive bladder cancer. |
What to Watch | Additional country launches, reimbursement access, treatment-centre adoption, distribution expansion and real-world clinical experience. |
Primary Source | ImmunityBio |
Primary Source URL | https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-first-patients-europe-treated-anktivar |
Relevant Date | 4 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
コメント